The Pharma Letter Podcast — Episode 20 — Galapagos update—with CEO Paul Stoffels

Simon Wentworth

2 February 2023

2-2

More on this story...

R&D U-turn sees Galapagos ditching liver and kidney programs

4 November 2022

Belgian biotech Galapagos goes on a spending spree

22 June 2022

NICE recommends Galapagos' Jyseleca in UC

1 June 2022

Strategic overhaul continues apace at Galapagos, with new R&D deal

31 March 2023

Companies featured in this story

More ones to watch >

More Features in Biotechnology

Former Mirati CMO Alan Sandler joins ALX Oncology

14 November 2024

Merck & Co wades into PD-1/VEGF space via deal with LaNova Medicines

14 November 2024

AC Immune Phase II ACI-7104.056 success in Parkinson’s

14 November 2024

The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies?

14 November 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze